NexImmune, Inc. announced that Jack A. Ragheb, MD, PhD, has been appointed to the newly created position of Senior Vice President, Translational Science, bringing more than 30 years of experience in translational and clinical research in the fields of cell therapy, gene therapy, immunology and virology. In addition, Matt Schiller has been appointed to Head of Business Development, bringing more than 20 years of business development experience across developmental stage life science companies and large pharma. Dr. Ragheb was most recently a Senior Medical Fellow for Immunology and Co-chair of the Immunogenicity/Immunosafety Working group at Eli Lilly. Prior to his time at Eli Lilly, Dr. Ragheb was a Chief Medical Research Officer in the Office of Biological Products with the Center for Drug Evaluation and Research at the U.S. FDA. He was previously a Senior Clinical Investigator at the National Eye Institute, NIH and an Attending Physician on the Allergy-Immunology Service of the National Institute of Allergy and Infectious Disease (NIAID), NIH. Mr. Schiller has over 20 years of experience in business development, global licensing and commercial development. Most recently, Mr. Schiller served as Director, Global Licensing &Business Development, Immunology at EMD Serono, a business of Merck KGaA. Prior to his time at EMD Serono, Mr. Schiller served as Head of Licensing at Cell Signaling Technology, VP of Business Development at Ensemble Discovery and Senior Director of Business Development at Critical Therapeutics.
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.